61762-39-8

Basic information

• Product Name: N-(2-Aminoethyl)myristamide
• Synonyms: N-(2-Aminoethyl)myristamide
• CAS NO: 61762-39-8
• Molecular Formula: C16H34N2O
• Molecular Weight: 270.45
• Mol File: 61762-39-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 150-152 °C(Solv: ethanol (64-17-5))
• Boiling Point: 426.7°C at 760 mmHg
• Flash Point: 211.9°C
• Appearance: /
• Density: 0.894g/cm³
• Vapor Pressure: 1.73E-07mmHg at 25°C
• Refractive Index: 1.463
• PKA: 15.89±0.46(Predicted)
• CAS DataBase Reference: N-(2-Aminoethyl)myristamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-Aminoethyl)myristamide(61762-39-8)
• EPA Substance Registry System: N-(2-Aminoethyl)myristamide(61762-39-8)

Safety Data

• Hazardous Substances Data: 61762-39-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H34N2O/c1-2-3-4-5-6-7-8-9-10-11-12-13-16(19)18-15-14-17/h2-15,17H2,1H3,(H,18,19)

Upstream product

• 110-36-1 n-butyl myristate 
• 107-15-3 ethylenediamine 
• 544-63-8 n-tetradecanoic acid 
• 124-10-7 methyl myristoate 
• 112-64-1 tetradecanoyl chloride 
• 1335231-54-3 C₂₁H₄₂N₂O₃ 

Downstream Products

• 21631-82-3 2-n-Tridecyl-2-imidazolin 

Relevant articles and documents

Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro

Isomalyngamide A (1) and A-1 (2) were isolated from the Taiwanese Lyngbya majuscule and the latter structure was elucidated by a combination of NMR spectroscopic analysis and HRESIMS measurement. We report the isolation of isomalyngamide A (1), discovery of isomalyngamide A-1 (2) and their synthetic analogs (3-9), which are further demonstrated to have therapeutic potential against tumor cell migration at the level of nanomolar to micromolar ranges, perhaps, by inactivating the expression of p-FAK, FAK, p-Akt and Akt through β1 integrin-mediated antimetastatic pathway.

Synthesis and biological evaluation of a new series of N-acyldiamines as potential antibacterial and antifungal agents

In continuation of our efforts to find new antimicrobial compounds, series of fatty N-acyldiamines were prepared from fatty methyl esters and 1,2-ethylenediamine, 1,3-propanediamine or 1,4-butanediamine. The synthesized compounds were screened for their antibacterial activity against Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa) and for their antifungal activity against four species of Candida (C. albicans, C. tropicalis, C. glabrata and C. parapsilosis). Compounds 5a (N-(2-aminoethyl)dodecanamide), 5b (N-(2-aminoethyl)tetracanamide) and 6d (N-(3-aminopropyl)oleamide) were the most active against Gram-positive bacteria, with MIC values ranging from 1 to 16 μg/mL and were evaluated for their activity against 21 clinical isolates of methicillin-resistant S. aureus. All the compounds exhibited good to moderate antifungal activity. Compared to chloramphenicol, compound 6b displayed a similar activity (MIC50= 16 μg/mL). A positive correlation could be established between lipophilicity and biological activity.

Glycosylation enhances the anti-migratory activities of isomalyngamide A analogs

Three, new, fully synthetic glycosylated isomalyngamide A analogs 4-6 were prepared and evaluated for their anti-migratory activities in human breast cancer cells. The results of the study show that two glycosylated derivatives 4 and 5, containing mannose and galactose appendages, suppress metastatic events (e.g., migration, invasion and adhesion) in human breast adenocarcinoma MDA-MB-231 cells at "nontoxic" concentration levels. In contrast, derivative 6 that contains a lactose moiety, displays a less potent activity. The findings show that monosaccharide rather than disaccharide appendages to the isomalyngamide A backbone more greatly influence cell migration and invasive ability. Evidence has been gained for a mechanism for inhibition of metastatic activities in MDA-MB-231 cells by 4 and 5, involving inactivation of the expression of p-FAK and paxillin through the integrin-mediated antimetastatic pathway.